Has George Keogh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $745,421 in general payments to George Keogh, MD across 1,071 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean George Keogh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about George Keogh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

George Keogh, MD

Hematology & Oncology · Charleston, SCNPI 1487611505

Payments from drug & device makers

$745,421in general payments, 2019–2025

Across 1,071 payments — averaging $696.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$354K
Bayer$162K
Merck$116K
Amgen$55K
Astellas Pharma Global Development$18K
Pfizer$12K
plus $27K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	85	$354,495
Bayer	38	$162,083
Merck	165	$115,948
Amgen	42	$54,764
Astellas Pharma Global Development	19	$17,684
Pfizer	43	$12,463
Seagen Inc.	23	$9,646
Incyte Corporation	51	$3,094
Genentech, Inc.	7	$1,887
Novartis	83	$1,594
Johnson & Johnson(2 entities)	75	$1,386
Gilead(2 entities)	26	$865
Bristol Myers Squibb	24	$575
GSK	25	$527
Lilly USA, LLC	18	$496
Mckesson Specialty Care Distribution, LLC	7	$466
Eisai Inc.	22	$464
Genentech USA, Inc.	25	$424
Sanofi	13	$419
Regeneron Healthcare Solutions, Inc.	22	$415
Takeda Pharmaceuticals U.S.A., Inc.	19	$396
AbbVie	20	$395
Daiichi Sankyo Inc.	12	$282
Rigel Pharmaceuticals, Inc.	11	$256
Array Biopharma Inc	15	$249
Puma Biotechnology, Inc.	12	$236
Jazz Pharmaceuticals Inc.	11	$216
ADC Therapeutics America, Inc.	10	$191
Foundation Medicine, Inc.	1	$175
Sobi, Inc	7	$163
Astellas Pharma US Inc	7	$151
Taiho Oncology, Inc.	7	$150
Acrotech Biopharma Inc.	5	$133
Pharmaessentia USA Corporation	6	$132
Medtronic(2 entities)	2	$117
Novocure Inc.	3	$107
Karyopharm Therapeutics Inc.	5	$107
Stemline Therapeutics Inc.	4	$103
Beone Medicines USA, Inc.	4	$102
Servier Pharmaceuticals LLC	5	$98
Boehringer Ingelheim	4	$92
Alnylam Pharmaceuticals Inc.	4	$91
LEO Pharma Inc.	1	$75
AVEO Pharmaceuticals, Inc.	3	$72
Epizyme, Inc.	5	$71
Apellis Pharmaceuticals, Inc.	2	$69
Deciphera Pharmaceuticals Inc.	2	$65
Sumitomo Pharma America, Inc.	2	$63
Pharmacyclics LLC, An Abbvie Company	4	$59
CSL Behring	2	$59
Recordati_rare_diseases_inc.	3	$56
Beigene USA, Inc.	3	$54
Shield Therapeutics Inc	3	$52
Morphosys, US Inc.	3	$50
Exelixis Inc.	3	$49
Myovant Sciences Inc.	2	$49
GE HealthCare	2	$49
Genmab U.S., Inc.	2	$47
Adaptive Biotechnologies Corporation	2	$47
Mirati Therapeutics, Inc.	2	$43

How this compares

$745,421 in reported general payments places this provider in the 90th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina →

Medicare billing

Part B allowed, 2024

$94,999

Medicare patients

372

Services billed

939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Charleston

Robert StuartCharleston$2.9M
Brian LingerfeltCharleston$1.1M
James OrcuttCharleston$1.1M
George GeilsCharleston$930K
John WrangleCharleston$919K
David EllisonCharleston$767K
Russell JenkinsCharleston$627K
Irl GreenwellCharleston$376K
Ming LimCharleston$341K
Young LeeCharleston$338K

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →